AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 51 min read$GEHC

GE HealthCare To Acquire SOFIE Biosciences For $945M;Stock Up

GE HealthCare (GEHC) agreed to buy SOFIE Biosciences for $945M in cash, expected to close by mid-2027. SOFIE operates 15 U.S. sites with 21 cyclotrons, expanding GEHC's radiopharmaceutical capabilities. The deal includes U.S. rights to FAPI-74, a Phase 3 PET radiotracer. GEHC shares rose 0.96% premarket.

Original reporting
rttnews.com
Published Oct 5, 2026, 1:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The $945M cash deal is expected to be accretive and may boost GEHC's share price in the short term.

02

Market read

A large‑cap M&A announcement with immediate price impact and sector‑wide implications.

03

What to watch

Regulatory approval risk and potential competition from emerging radiotracer technologies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

GE HealthCare is expanding its pharmaceutical diagnostics business through acquisitions.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences for $945M, a new primary M&A disclosure.

Expected impact

likely modest upside as investors price in the accretive acquisition.

Evidence & confidence

Large‑cap deal, cash transaction, and pre‑market price rise indicate positive market reaction.

Market effects

Sector

Strengthens GEHC's position in the PET radiopharmaceutical market, potentially pressuring peers.

Regional

Adds to U.S. radiopharma capacity, may influence domestic supply dynamics.

Global

Highlights continued consolidation in the global nuclear medicine sector.

Counterpoint

What could challenge this read

Deal could strain GEHC's balance sheet if integration costs exceed expectations.

Key entities

  • Company
    GE HealthCare Technologies Inc.

    US‑listed medical imaging and diagnostics firm (ticker GEHC).

  • Company
    SOFIE Biosciences

    Private PET radiopharmaceutical manufacturer being acquired.

Read at source← All news

StoryGE HealthCare agrees $945 million purchase of SOFIE Biosciences

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min